Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

June 6, 2023

Study Completion Date

June 6, 2023

Conditions
Prostate Cancer
Interventions
DRUG

Copper-64 labelled SAR-Bombesin

radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.

Trial Locations (1)

2010

St Vincent's Hospital, Sydney

Sponsors
All Listed Sponsors
collaborator

Clarity Pharmaceuticals Ltd

INDUSTRY

lead

St Vincent's Hospital, Sydney

OTHER